Last updated: February 15, 2026
Drug Overview
NDC 70000-0147 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy indicated for spinal muscular atrophy (SMA) in pediatric patients. Covering a one-time infusion, Zolgensma targets the genetic root cause of SMA, offering a potentially transformative treatment.
Market Size and Competitors
SMA Market Dynamics:
- Estimated global SMA prevalence: approximately 1 in 10,000 live births.
- US population of infants and children at risk: about 4 million annually.
- The SMA patient population suitable for gene therapy (symptomatic and presymptomatic): estimated at 300-400 patients yearly in the U.S. alone.
Key Competitors:
- Biogen's Spinraza (nusinersen): Administered via multiple injections over time, with US sales of $592 million in 2022.
- Novartis's Evrysdi (risdiplam): Oral therapy, US sales at approximately $468 million in 2022.
While Spinraza and Evrysdi remain primary treatments, Zolgensma's one-time administration positions it differently in the market.
Price and Reimbursement Landscape
Current Pricing:
- The U.S. list price for Zolgensma: approximately $2.1 million per dose (single administration).
- Pricing in Europe and other regions varies, typically matching or slightly below U.S. levels, adjusted for local healthcare economics.
Reimbursement Policies:
- Insurance companies and government payers have negotiated outcomes-based agreements.
- In the U.S., pricing often tied to outcomes; full reimbursement occurs when treatment demonstrates expected clinical benefits.
Market Penetration and Adoption Trends
- Zolgensma has received FDA approval since May 2019.
- Adoption has increased as awareness and clinical experience grow.
- Constraints include high costs, limited supply, and specific patient eligibility criteria.
Price Projections (2023-2028)
| Year |
Estimated Average Price |
Market Penetration |
Notes |
| 2023 |
$2.1 million |
40% of eligible patients |
Steady increase as physician familiarity improves. |
| 2024 |
$2.0 million |
50% |
Slight price stabilization; broader access. |
| 2025 |
$1.9 million |
60% |
Price reductions due to market competition and negotiations. |
| 2026 |
$1.8 million |
70% |
Continued growth in market share; potential biosimilar or alternative therapies. |
| 2027 |
$1.7 million |
80% |
Further acceptance; potential value-based payment models expand. |
| 2028 |
$1.6 million |
85% |
Maturation of market; price reductions expected as competition increases. |
These projections assume ongoing reimbursement negotiations and broadening indications, including extended age groups and presymptomatic treatment.
Market Challenges and Opportunities
- Challenges:
- High upfront cost limits immediate adoption.
- Manufacturing complexities and supply constraints.
- Payer resistance to high-cost therapies.
- Opportunities:
- Expanded indications could increase eligible patients.
- Outcomes-based reimbursement models may reduce payer risk.
- Advances in gene therapy manufacturing may reduce costs over time.
Regulatory Environment
- Continued approvals across multiple countries.
- Favorable inclusion in newborn screening programs enhances early diagnosis and treatment rates.
- Pending applications for extended age groups and indications.
Key Takeaways
- Zolgensma remains the most expensive gene therapy with a $2.1 million one-time dose.
- Market adoption is increasing, driven by better diagnosis, payer negotiations, and clinical outcomes.
- Price projections show gradual reductions, influenced by competition, manufacturing efficiencies, and reimbursement strategies.
- The global SMA market is growing, with regulatory and clinical developments supporting expanded treatment options and pricing models.
FAQs
1. What factors influence the pricing of Zolgensma?
Pricing is affected by manufacturing costs, reimbursement negotiations, clinical value, competitor prices, and market access strategies.
2. How does Zolgensma compare to Spinraza and Evrysdi?
Zolgensma is a one-time infusion costing around $2.1 million. Spinraza and Evrysdi require ongoing administration, resulting in higher total costs over time.
3. What is the outlook for biosimilars or competitors?
No biosimilars exist yet due to the nature of gene therapies. Future competitors may include other gene therapies or cheaper manufacturing processes.
4. How significant is the role of newborn screening?
It is crucial; early diagnosis via newborn screening increases treatment eligibility and efficacy, expanding the market.
5. What are reimbursement trends for high-cost gene therapies?
Payers increasingly favor outcomes-based models, with negotiations for installment payments or value-based pricing to mitigate financial risk.
References
- FDA Approval of Zolgensma
- Pricing Data for Zolgensma
- Market Data on SMA Treatments
- Reimbursement Trends
